Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Interim results from a muticenter prospective cohort study.
用户dezZ-X6r0Kf0
5小时前
19
10
已关闭
DOI: 10.1200/jco.2020.38.15_suppl.4580
文献链接: https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.4580
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Jin-hong Chen; Lu Lu; Tian-Fu Wen; Zhi-Yong Huang; Ti Zhang; Yong-Yi Zeng; Xiang-Cheng Li; Bang-De Xiang; Cai-de Lu; Xiao Xu; Lun-xiu Qin